Chairman & Chief Executive Officer
Chief Medical Officer
Chief Business Officer & Head of Finance
Vice President of Finance & Controller
Vice President, Intellectual Property & Licensing
General Manager, Shenzhen EXUMA Biotech
© Copyright 2025 EXUMA Biotechnology. All rights reserved.
Chairman & Chief Executive Officer
Gregory Frost, Ph.D. has served as Chairman and CEO of EXUMA Biotech since 2015. Dr. Frost has over 25 years of experience in the biotechnology industry, over a decade of which leading public biotechnology companies, where he helped create over $6B worth of shareholder value during his tenure. Dr. Frost was CEO at Halozyme Therapeutics (NASDAQ:HALO), an S&P 400 San Diego public biotechnology company he co-founded in 1999 to enable subcutaneous biologics delivery. He served in various operational roles over 15 years through multiple internal and partnered product approvals that are marketed in over 100 countries today.
Dr. Frost earned his B.A. in biochemistry and molecular biology from UCSC, his Ph.D. in the Department of Pathology at UCSF and performed postdoctoral research at the Sidney Kimmel Cancer Center. He sits on the Board of Governors at BioCom and is managing director of F1BioVentures, LLC.
Chief Medical Officer
Dr. Wendy Li rejoined EXUMA Biotech as Chief Medical Officer in June 2024. She brings over 20 years of experience in global clinical and medical strategy management, spanning early to late-stage development of MNC pharmaceutical companies in the U.S. and Asia. Dr. Li’s expertise spans clinical development and medical affairs, where she has led numerous global clinical trials targeting hematological malignancies, solid tumors, and autoimmune disorders. She has successfully overseen and led multiple global therapeutic Investigational New Drug (IND) applications, New Drug Applications (NDA), and Biologics License Applications (BLA).
Before rejoining EXUMA, Dr. Li served as CMO for Gracell Biotechnologies, providing deliberate medical and clinical leadership for the cell therapy pipeline and strategies in the U.S. and Asia. She has also held leadership roles in clinical development and medical affairs at Pfizer, Sanofi, Genentech, and Sihuan Pharmaceutical. Dr. Li earned her M.D. from Sun Yat-Sen University of Medical Sciences.
Chief Business Officer & Head of Finance
Dr. Wade serves as EXUMA Biotech’s Chief Business Officer and Head of Finance, having joined the company in 2022. Dr. Wade brings over 20 years of experience in the biotechnology industry. Most recently, he held the position of Managing Director, Capital Markets Advisory, and Co-Lead of the West Coast Region for Danforth Advisors. From 2015-2021, Dr. Wade was a Managing Director in BTIG’s Healthcare Investment Banking Group. Prior to his role with BTIG, Dr. Wade served as Head of Business Development at Pharmacyclics, a role he held following 16 years of work in healthcare equity research at Pacific Growth Equities and its successor, Wedbush PacGrow.
Dr. Wade earned his undergraduate degree in biophysics, and his Ph.D. in physiology, both from Western University in London, Canada.
Vice President of Finance & Controller
Mr. Yan is a certified public accountant with over 25 years of experience in finance & accounting. He joined EXUMA Biotech in 2017 and currently serves as its Vice President of Finance & Controller, a role in which he oversees the finance, accounting, budgeting, tax, and treasury functions at all Company locations. Prior to joining EXUMA, he served in a similar role managing worldwide accounting, tax, and treasury functions at Premis Capital Partners. He began his career at Ernst & Young where he managed audit engagements.
Mr. Yan earned his B.B.A in accounting from Florida Atlantic University and has been a licensed certified public accountant since 1999.
Vice President, Intellectual Property & Licensing
Dr. Schreiber joined EXUMA Biotech in April 2016 and currently serves as its Vice President of Intellectual Property & Licensing. In his previous leadership roles over the past two decades at Intrexon Corporation, Thermo Fisher Scientific, and Johns Hopkins University, he led the licensing efforts that formed the basis of more than a dozen commercial products.
Dr. Schreiber received his B.A. in biochemistry from the University of California, Berkeley and his Ph.D. in immunology from Washington University in St. Louis. Additionally, he is registered to practice before the U.S. Patent and Trademark Office.
General Manager, Shenzhen EXUMA Biotech
Dr. Shi is the General Manager of Shenzhen EXUMA Biotech, overseeing supply chain, manufacturing, quality control, and site operations at the Company’s lentivector manufacturing facility. Prior to EXUMA, he served as Vice President, CMC and Site Head of EdiGene where he led the development of the first gene editing HSC therapy in China. Prior to that, he held R&D and QA roles at Xiangxue Pharmaceutical in which he was responsible for the development of analytical methods for TCR-T product manufacturing; his work led to the first IND approval for a TCR-T product candidate in China.
Dr. Shi received his Ph.D. in physiology from China Agriculture University and holds the Senior Specialized Technique Qualification from the Beijing Municipal Medical Products Administration.
Chairman & Chief Executive Officer
Gregory Frost, Ph.D. has served as Chairman and CEO of EXUMA Biotech since 2015. Dr. Frost has over 25 years of experience in the biotechnology industry, over a decade of which leading public biotechnology companies, where he helped create over $6B worth of shareholder value during his tenure. Dr. Frost was CEO at Halozyme Therapeutics (NASDAQ:HALO), an S&P 400 San Diego public biotechnology company he co-founded in 1999 to enable subcutaneous biologics delivery. He served in various operational roles over 15 years through multiple internal and partnered product approvals that are marketed in over 100 countries today.
Dr. Frost earned his B.A. in biochemistry and molecular biology from UCSC, his Ph.D. in the Department of Pathology at UCSF and performed postdoctoral research at the Sidney Kimmel Cancer Center. He sits on the Board of Governors at BioCom and is managing director of F1BioVentures, LLC.
Dr. McCormick joined EXUMA Biotech as a Director in February 2020 and currently holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF where he serves as a Professor at the Helen Diller Family Comprehensive Cancer Center, after having previously served as the center’s director. Prior to joining UCSF, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held leadership positions with Cetus Corporation and Chiron Corporation. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated drug discovery efforts that led to the approval of Sorafenib for the treatment of renal cell and liver cancer, and the approval of ONYX-015 in China for the treatment of nasopharyngeal cancer. In addition, his group’s work led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Having authored over 330 scientific publications and holding over 20 issued patents, Dr. McCormick’s current research focuses on ways of targeting Ras proteins and their regulators, whereby he leads the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research to develop therapies against Ras-driven cancer.
Dr. McCormick earned his B.Sc. In biochemistry from the University of Birmingham, England and his Ph.D. in biochemistry from the University of Cambridge, England. He is a Fellow of the Royal Society and a member of the National Academy of Sciences, and served as president for the American Association for Cancer Research from 2012-2013.
Mr. Ramsay has been a Director of EXUMA Biotech since January 2017. In 2018, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. Mr. Ramsay retired from Halozyme Therapeutics, Inc. (NASDAQ: HALO) in July 2015, where he served as Chief Financial Officer since May 2013 and from 2003-2009. He also served as Halozyme’s Vice President, Corporate Development from 2009-2013. From 2000-2003, Mr. Ramsay was Vice President and Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life science industry. From 1998-2000, he was with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), where he served as Vice President, Treasurer and Director, Corporate Finance. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his C.P.A. license. Mr. Ramsay also serves on the boards of Savara Pharmaceuticals (NASDAQ: SVRA) and La Jolla Pharmaceutical (NASDAQ: LJPC).
Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and a M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.
Dr. Flynn was the founder of Deciphera Pharmaceuticals and served as Executive Vice President and Chief Scientific Officer of the company since January 2019, as well as Chief Scientific Officer since March 2014. He previously held the positions of President and Chief Executive Officer from November 2003 to March 2014 and was a member of the company’s Board of Directors from November 2003 to September 2015. Before founding the company in 2003, Dr. Flynn held senior roles in small molecule chemistry at various biotechnology and pharmaceutical companies, including Senior Director of Chemistry at Millennium Pharmaceuticals, Director of Medicinal Chemistry at Amgen Inc., and Director of Medicinal Chemistry, Combinatorial Chemistry, and Research Fellow at Monsanto Company, G.D. Searle Unit.
Dr. Flynn is currently an Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society. He received both his Ph.D. in medicinal chemistry and his B.S. in pharmacy from the University of Kansas and completed post-doctoral training in synthetic organic chemistry at Indiana University.
Dr. Holmes joined EXUMA Biotech as a Director in December 2021. He is a hematologist/oncologist at Texas Oncology, where he serves on the Board of Directors and Executive Committee, and he is Area Medical Director of the Baylor/Sammons Cancer Center in Dallas. His clinical focus is in research and development of cell therapies for cancer.
Dr. Holmes received a B.S. in medical microbiology from Stanford University, an M.D. from the University of Texas Southwestern Medical School, and an M.B.A. from the University of Texas at Dallas. He completed an internship and residency in internal medicine at Baylor University Medical Center, and fellowship in medical oncology/hematology at the National Cancer Institute/National Heart, Lung, and Blood Institute. Dr. Holmes is a Fellow of the American College of Physicians.
Dr. Lawrence Steinman was appointed to EXUMA’S Scientific Advisory Board in November 2024. Dr. Steinman is a professor of neurology and neurological sciences, pediatrics, and genetics at Stanford University Medical School. Dr. Steinman has received numerous honors and awards, including election to the National Academy of Sciences and the National Academy of Medicine. He is the recipient of the John Dystel Prize from the American Academy of Neurology and the National Multiple Sclerosis Society for his research on multiple sclerosis, the Charcot Award from the Multiple Sclerosis International Federation, and the Anthony Cerami Award in Translational Medicine from Molecular Medicine.
Dr. Steinman received his BA from Dartmouth College and his MD from Harvard University. He was a post-doctoral fellow in chemical immunology fellow at the Weizmann Institute of Science in Israel. Dr. Steinman returned to Stanford University Hospital as a resident in pediatric and adult neurology and then joined the faculty at Stanford in 1980.
Dr. Steinman holds a number of patents in the areas of immunology, and for therapies of Huntington Disease, type 1 diabetes and MS. He cofounded public traded companies including Neurocrine Biosciences and Pasithea Therapeutics. He was a Board Member at Centocor until acquired by Johnson and Johnson.
Dr. Shepard was appointed to EXUMA’S Scientific Advisory Board in May 2020. At Genentech, he and a team of researchers discovered Herceptin (trastuzumab), the first monoclonal antibody to block a cancer-causing protein, and developed it into a life-saving therapy for women with breast cancer. In 2019, Dr. Shepard and two other scientists were awarded the Lasker–DeBakery Clinical Medical Research Award, and in 2006, Dr. Shepard and his research team were awarded Harvard Medical School’s Alpert Prize for this work. He has been a founder or principal in several biotech companies including Canji, Inc., NewBiotics, Receptor Biologix, and Halozyme. Dr. Shepard is a frequent guest lecturer and has co-authored many peer-reviewed publications and patents.
Dr. Shepard received his undergraduate degree from the University of California, Davis and his Ph.D. from Indiana University, where he was a Damon Runyon Cancer Research Foundation fellow.
